Protagenic Therapeutics, Inc. PTIX
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.43M | 2.39M | 3.74M | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.12M | 3.37M | 4.76M | -- | -- |
| Operating Income | -3.12M | -3.37M | -4.76M | -- | -- |
| Income Before Tax | 5.46M | 1.37M | -5.55M | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 5.46 | 1.37 | -5.55 | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 5.46M | 1.37M | -5.55M | -- | -- |
| EBIT | -3.12M | -3.37M | -4.76M | -- | -- |
| EBITDA | -3.08M | -3.32M | -3.21M | -- | -- |
| EPS Basic | 2.83 | 2.00 | -1.04 | -- | -- |
| Normalized Basic EPS | -0.28 | -0.61 | -0.46 | -- | -- |
| EPS Diluted | 2.83 | 2.00 | -1.04 | -- | -- |
| Normalized Diluted EPS | -0.28 | -0.61 | -0.46 | -- | -- |
| Average Basic Shares Outstanding | 7.48M | 9.37M | 12.79M | -- | -- |
| Average Diluted Shares Outstanding | 7.48M | 9.37M | 12.79M | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |